Furmonertinib + Anlotinib
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer
Conditions
Non-Small-Cell Lung Cancer
Trial Timeline
Oct 12, 2021 → Nov 30, 2023
NCT ID
NCT04895930About Furmonertinib + Anlotinib
Furmonertinib + Anlotinib is a phase 2 stage product being developed by Shanghai Allist Pharmaceuticals for Non-Small-Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04895930. Target conditions include Non-Small-Cell Lung Cancer.
What happened to similar drugs?
7 of 20 similar drugs in Non-Small-Cell Lung Cancer were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
12
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04895930 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer